Edgewise Therapeutics: Upcoming DMD Trial Data May Disappoint

2025-05-29 12:47:48 ET

Summary

• Edgewise Therapeutics' valuation is heavily reliant on DMD/BMD programs, with upcoming phase-2 readouts likely to disappoint and trigger a sharp stock decline.
• We believe that sevasemten's mechanism lacks convincing human efficacy data, and prior muscle-preservation approaches in DMD have failed to show functional benefit.
• Recent trial delays, endpoint changes, and noisy biomarker data undermine confidence in sevasemten’s prospects; functional data show no meaningful improvement over placebo in BMD.
• HCM asset EDG-7500 faces safety concerns and could lack clear differentiation from competition.

“Etymologically, patient means sufferer. It is not suffering as such that is most deeply feared but suffering that degrades.” ...

Read the full article on Seeking Alpha

For further details see: